Business Wire

Pharnext’s PLEODRUG™ PXT3003 to be Featured at the Upcoming Hereditary Neuropathy Foundation (HNF) Annual Patient-Centered Summit

Jaa

Regulatory News:

Pharnext SA (FR0011191287 - ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that it will participate at the upcoming Hereditary Neuropathy Foundation (HNF) Annual Patient-Centered Summit for Charcot-Marie-Tooth (CMT) and Hereditary Neuropathy With Liability To Pressure Palsies (HNPP), on November 3, 2017, in Boston (United States). Pharnext will present, in a poster and during an oral session, an update on its ongoing pivotal Phase 3 clinical trial evaluating its lead PLEODRUG™ PXT3003, in development for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A).

This unique event will bring together patients, caregivers, industry representatives, researchers and clinicians. This year, the summit will focus on pain. The objective is to come to an understanding of pain in the CMT/HNPP Community, including its impact on quality of life.

Details of the presentations are as follows:

  • Oral Session, November 3, 2017, from 4.15pm to 5.15 pm EST
    • Title : Update on Current Clinical Trials for CMT/HNPP
    • Presenters : René Goedkoop, MD, Chief Medical Officer, Pharnext, France and Kenneth Attie, MD, VP-Medical Research, Acceleron, United States
  • Poster session, November 3, 2017, all day
    • Title : “Status of the ongoing phase III study assessing the efficacy and safety of PXT3003 for CMT1A (PLEOCMT).” S. Attarian et al.
    • Presenter: René GoedKoop, MD, Chief Medical Officer, Pharnext, France

For more information about the event please visit https://www.hnf-cure.org/cmtsummit/summit2017/

About Hereditary Neuropathy Foundation
Hereditary Neuropathy Foundation (HNF) is a US non-profit 501(c)3 organization whose mission is to increase awareness and accurate diagnosis of Charcot-Marie-Tooth disease (CMT) and related inherited neuropathies, support patients and families with critical information to improve quality of life, and support research. HNF has notably developed the Therapeutic Research in Accelerated Discovery (TRIAD) program, a collaborative effort with academia, government, and industry to support and develop treatments for CMT. For further information, visit www.hnf-cure.org

About PXT3003
PXT3003, developed using Pharnext’s R&D platform PLEOTHERAPY™, is a novel oral fixed-low dose combination of (RS)-baclofen, naltrexone hydrochloride and D-sorbitol with Orphan Drug Designation in Europe and the United States.

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit www.pharnext.com

Contact information

Pharnext
René GoedKoop, +33 (0)1 41 09 22 30
Chief Medical Officer
medical@pharnext.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
matthew@sternir.com
or
Financial Communication (France)
Actifin
Stéphane Ruiz, +33 (0)1 56 88 11 15
sruiz@actifin.fr
or
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol
Margaux Pronost
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Media Relations (U.S.)
RooneyPartners
Marion Janic, +1 212 223 4017
mjanic@rooneyco.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

QNB Group: Financial Results for the Year Ended 31 December 201716.1.2018 16:26Tiedote

QNB Group, the largest financial institution in the Middle East and Africa (MEA) region, announced its results for the year ended 31 December 2017. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116006048/en/ QNB Group HQ Building in Doha (Photo: AETOSWire) For the year ended 2017, Net Profit reached QAR13.1 billion (USD3.6 billion), up by 6% compared to last year. Total assets increased by 13% from December 2016 to reach QAR811 billion (USD223 billion), the highest ever achieved by the Group. The Board of Directors have recommended to the General Assembly for the distribution of a cash dividend of 60% of the nominal share value (QAR 6.0 per share). The financial results for 2017 along with the profit distribution are subject to Qatar Central Bank (QCB) approval. Key driver of total assets growth was from loans and advances which grew by 12% to reach QAR584 billion (USD161 billion). Also QNB Group increased customer deposi

H.I.G. Capital Acquires Majority Stake in Beinbauer Group16.1.2018 15:35Tiedote

H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €20 billion of equity capital under management, announced that one of its affiliates has acquired a majority interest in Beinbauer Group (“Beinbauer”). Beinbauer, headquartered in Büchlberg near Passau, Germany, is a leading provider of complex machined metal parts (iron, steel, aluminium) for the European on- and off-highway commercial vehicle industry (OEMs and other tier-1 suppliers). Beinbauer’s core competencies are the machining of components and assemblies in state-of-the-art production processes as well as building and managing complex supplier networks, offering its customers all-in-one solutions for axle, frame, chassis and engine parts from a single source. Beinbauer operates four production sites in Germany and has approximately 700 employees. In 2017, Beinbauer generated revenues of more than €200 million. The Beinbauer management team, headed by Tobias Lührig and Patric Meeth, will c

Bidgely Closes $27M Series C to Grow Artificial Intelligence Solution for Utilities and Energy Retailers16.1.2018 14:00Tiedote

U.S.-based Bidgely announced today the closing of a $27 million Series C round of financing, marking the largest round of investment to date for any energy disaggregation technology. Georgian Partners, an investment fund known for its focus on high-growth enterprise software companies that use applied artificial intelligence to disrupt markets, led the oversubscribed round. Returning investors include Khosla Ventures, E.ON, and innogy. Constellation Technology Ventures, the venture capital arm of Exelon Corporation, is also expected to return. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116005615/en/ Bidgely Energy Usage Itemisation (Photo: Business Wire) “We invest in high-growth SaaS companies that are applying AI to solve real-world business problems,” said Simon Chong, Managing Partner at Georgian Partners. “Bidgely is using machine learning to fundamentally reinvent customer engagement with utilities and enable a n

Glennmont Seeks More Than 500MW of Investment Opportunities in Clean Energy Infrastructure Assets with Expanded Investment Capacity16.1.2018 13:19Tiedote

Glennmont Partners has expanded its investment capacity in the clean energy infrastructure space and now has three funds under management – these are Fund I (2010) and Fund II (2013), which are fully invested, and now a new third Fund (2017). Opportunities are being sought for a portfolio of clean energy infrastructure projects in Europe. Glennmont is one of Europe’s largest investors focusing exclusively on investment in clean energy infrastructure. This announcement follows the successful refinancing of Glennmont’s 245MW Italian wind portfolio in October and the refinancing of the Sleaford straw-fired biomass plant in September - amounting to around €340m of capital raised over the course of 2017. Glennmont’s strategy remains consistent with its past experiences: it seeks to invest in solar PV, offshore and onshore wind, bioenergy and small-scale hydro across the EEA; it will target to-be-built and recently operational assets with stable, predictable cash yields underpinned by regula

Breed Reply Portfolio of IoT Start-Ups Raise in Excess of $50 Million in Series A Funding in 201716.1.2018 13:00Tiedote

Breed Reply, a leading operational investor in early-stage internet of things (IoT) businesses, saw one third of its 18-strong portfolio of investee companies, complete series A funding rounds in 2017. In total, six companies raised in excess of $50 million during the year with funds coming from notable investors including Accel, Aviva Ventures, Finance Wales, Intu and MunichRE. More companies in the growing portfolio are expected to be ready for Series A investment in 2018. The successful companies span a broad range of IoT sectors: Callsign (Cyber Security); Cocoon (Smart Home); enModus (Smart Building); Senseye (Industrial); WePredict (Big Data); and Zeetta Networks (Platforms). Helping start-ups prepare for future funding is a crucial part of Breed Reply’s commitment to companies when it invests. As an active operational investor, Breed Reply works closely with management to accelerate the company’s development to achieve Series A funding and beyond. The team has significant experi

MagicStay Raises 1.5 Million Euros to Accelerate Its Development16.1.2018 13:00Tiedote

The short-term rental start-up for business travelers MagicStay.com , has just finalized a new round of fundraising to continue its development. Just four years since its release, the rental platform already offers 150,000 apartments in 90 countries and has taken a leading position in the alternative accommodation industry. The fundraising totaling 1.5 million Euros was led by the start-up’s main shareholders (Michaël Benabou, Benoit Bassi, Patrick Lucas, Nicolas Quenedey or Charles Petruccelli, former CEO of American Express Global Business Travel...), as well as new investors, including Marc Frappier, Managing Partner of Eurazeo and Head of Eurazeo Capital, Thibault Basquin, Managing Director of Ardian, Nicolas Santi-Weil, CEO of AMI Paris... This round table will let the start-up accelerate its exclusive technological development for employees of large companies to book secure apartments as easily as hotel rooms, via either existing booking tools (Hotel Booking Tool, Self Booking To

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme